23/100Is HROW-Harrow, a buy?
Sunday 13 September 2026
Why now: Commercial progress in dry eye, retina, and cataract products remains the reason to monitor Harrow, but the immediate setup is weak after a 5.7% premarket drop to $34.48 and sustained relative underperformance. The near-term test is whether new products and expanded coverage can turn demand into reported profit and cash generation.
Upside: The average Wall Street target is $65.33, implying 89.5% upside from the live $34.48 print. That upside assumes management delivers its growth plan, integrates TYRVAYA successfully, and reduces the gap between commercial demand and reported earnings.
Risks: Debt is the central financial risk, with net debt relative to earnings before interest, taxes, depreciation, and amortization extremely high. Execution risk is also elevated because the company is adding products and sales capacity while its reported operating results remain weak.
Sign up or log in for access
Unlock the full scorecard, detailed analysis, and research notes. Free — no credit card needed.
Scorecard
| Scorecard | 23/100 | |
|---|---|---|
| Company Detail | HROW - Harrow, Inc. | |
| Price as at 11 September 2026 | $34.48 | |
| Market cap | $1.3B | |
| Quality and Fundamental Score (100) | ||
| Breakout / Early-Momentum /20 | 0/20 | |
| Rev/EPS Momentum /20 | 0/20 | |
| Business Quality /15 | 9/15 | |
| Balance Sheet /15 | 3/15 | |
| Valuation /10 | 3/10 | |
| Industry Relative Strength /10 | 2/10 | |
| Macro / Sector Tailwind /10 | 6/10 | |
| Growth | ||
| Cash runway | Cash generative | |
| Revenue YoY | +36.4% | |
| EPS YoY | +71.4% | |
| FCF YoY | +170.2% | |
| Gross margin | 75.1% | |
| Valuation & Trend | ||
| Trailing P/E | neg | |
| Forward P/E | — | |
| RSI (14d) | 33 | |
| vs 50d SMA | -14.6% | |
| Support cushion | −2.1% | |
| Sentiment | ||
| Wall Street verdict | Mixed | |
| News tone | Quiet | |
| Dividend | — | |
How are these colored?
| Metric | Strong metrics | Solid metrics | Selective | Caution | Unfavourable |
|---|---|---|---|---|---|
| Overall score | ≥ 80 | 70-79 | 60-69 | 50-59 | < 50 |
| Business quality /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Balance sheet /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Market cap | ≥ $20B | $5B-$20B | $2B-$5B | $1B-$2B | < $1B |
| Cash runway | ≥ 3 yr or cash generative | 1.5-3 yr | 0.75-1.5 yr | 0.25-0.75 yr | < 0.25 yr |
| Revenue YoY | ≥ 15% | 5-15% | 0-5% | -5-0% | < -5% |
| EPS YoY | ≥ 20% | 5-20% | 0-5% | -5-0% | < -5% |
| FCF YoY | ≥ 10% | 1-10% | 0-1% | -5-0% | < -5% |
| Gross margin | ≥ 60% | 40-60% | 25-40% | 10-25% | < 10% |
| Trailing P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| Forward P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| RSI (14d) | 50-70 | 45-50 or 70-75 | 40-45 or 75-78 | 30-40 or 78-80 | < 30 or > 80 |
| vs 50d SMA | +2% to +15% | 0-2% or 15-25% | -2-0% or 25-35% | -3--2% or 35-40% | < -3% or > 40% |
| Support cushion | 2-10% above | 0-2% | 10-15% | 15-20% | price below support |
| Wall Street verdict | Aligned | — | Mixed | — | Disagrees |
| News tone | Positive | — | Neutral / Mixed | — | Negative |
| Dividend | Yield ≥ 2% & growing | Growing | Flat payer ≥ 1% | Low / flat | Cutting |
Detailed Analysis — Sunday 13 September 2026
Francis W.
Andrew R.
Receiver of capital expenditure: No: Harrow mainly sells medicines and pharmacy services, so demand depends on patient treatment volumes, reimbursement, and physician adoption rather than large customer capital-spending budgets.
Main customers
- Ophthalmologists and optometrists (They prescribe Harrow's branded and compounded eye-care therapies.)
- Outpatient surgery centers and retinal practices (They use products such as IHEEZO and TRIESENCE in cataract and retinal procedures.)
- Patients with dry eye and retinal disease (They are the end users of branded therapies including VEVYE, TYRVAYA, and retinal products.)
Notable contracts
- Global rights acquisition for TYRVAYA (Harrow announced the acquisition of global rights to the dry-eye nasal spray, with closing expected in the second half of 2026.)
- Canadian licensing arrangement with Apotex (Apotex holds Canadian rights to selected Harrow eye-care products, including VEVYE, IHEEZO, VERKAZIA, and ZERVIATE.)
- Harrow has built a concentrated eye-care platform with branded dry-eye, cataract, and retina products alongside a large compounding-pharmacy customer base.
- VEVYE, IHEEZO, TRIESENCE, BYOOVIZ, and the pending TYRVAYA addition give the company several ways to grow without relying on a single drug.
- The long-term opportunity is credible because eye-care specialists need differentiated products and reimbursement-supported treatment options.
- The investment case remains incomplete because the company must prove that portfolio growth can cover its enlarged operating cost base and debt burden.
Scores 23 out of 100. a mixed overall grade. Business quality and sector fit were fair but not standout drivers. Valuation and balance sheet weighed on the total. The score is capped by a weak balance sheet, continuing reported losses, very high debt relative to earnings before interest, taxes, depreciation, and amortization, substantial five-year share dilution, and a clearly broken stock trend. The product portfolio has real commercial momentum, but it has not yet translated into durable reported profitability. Mechanical cap: latest annual net income ≤ 0. Balance Sheet ≤ 3/15, Rev/EPS ≤ 0/20, overall ≤ 50/100.
Component scores are on the scorecard above.
- The chart does not support a constructive technical score.
- HROW fell 11.3% over 20 trading days and 14.2% over 90 trading days, has no confirmed breakout or recent recovery of the 50-day average, and its 200-day average is not rising.
- The September 12 premarket print of $34.48 was down 5.7% from the prior close, adding to an already weak trend.
- Annual revenue was $272.30 million and trailing free cash flow was positive at $42.76 million, while gross margin was a healthy 75.1%.
- Those strengths are offset by a $5.14 million annual net loss, negative returns on equity and assets, and a share count that increased 41.96% over five years.
- Cash was $83.89 million and the current ratio was 2.24, but total liabilities of $401.97 million nearly matched total assets of $416.82 million, while net debt relative to earnings before interest, taxes, depreciation, and amortization was 48.37.
Cash runway: Cash generative (latest annual free cash flow is positive).
Upcoming (1–6 months)
- Management presentation at the H.C. Wainwright Global Investment Conference on September 15, 2026, and any update on the TYRVAYA transaction close.
- Fourth-quarter 2026 clinical data expected from the IHEEZO QUELL study and the NATACYN investigator-initiated study.
Ongoing
- Reported revenue conversion, operating cash flow, debt levels, and whether branded-product demand produces sustained profitability.
- The stock's ability to reclaim and hold above the prior close of $36.58 after the September 12 premarket decline.
Risks
- The company may fail to convert product demand into sustainable earnings as selling, research, interest, and acquisition costs rise.
- Reimbursement changes, regulatory issues in pharmacy operations, or slower physician adoption could reduce demand for key products.
- Further acquisitions or financing could increase debt or dilute shareholders again.
Breaks the thesis
- A sustained break below $34.00 without a clear business-specific explanation would confirm that the downtrend remains in control.